LA JOLLA, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage
biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report
second quarter 2017 financial results after the close of U.S. financial markets on August 7, 2017. Kura Oncology’s management will
host a webcast and conference call at 4:30 p.m. EDT/1:30 p.m. PDT that day to discuss the financial results and provide a corporate
update.
The live call may be accessed by dialing 877-516-3514 for domestic callers and 281-973-6129 for international
callers and entering the conference code: 61058165. A live webcast and archive of the call will be available online from the
investor relations section of the company website at www.kuraoncology.com. A telephone replay of the call will be available by dialing 855-859-2056
for domestic callers or 404-537-3406 for international callers and entering the conference code: 61058165.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision
medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer
signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most
likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is
currently being studied in multiple Phase 2 clinical trials. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a
Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For
additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 robert.uhl@westwicke.com CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849-5375 mark@canalecomm.com